Most pharma AI pilots do not make it to production. The headlines focus on the technology. The honest math focuses on the dollars.
According to S&P Global Market Intelligence's 2025 survey, the average sunk cost per abandoned enterprise AI initiative is 7.2 million dollars. Projects that reach completion but fail to deliver value cost an average of 6.8 million dollars. In financial services, a single abandoned AI project costs an average of 11.3 million dollars.
This is the honest baseline. Now apply it to pharma.
The Pharma Failure Rate
The numbers across pharma specifically are starker than the cross industry average.
MIT's NANDA initiative published research in 2025 finding that 95 percent of enterprise GenAI pilots fail to scale to production deployment and deliver zero measurable return on the profit and loss statement. Cloudera's life sciences research found 80 percent of pharma AI projects fail to scale beyond the pilot phase. RAND Corporation's 2025 analysis found 80.3 percent of AI projects across industries fail to deliver intended business value.
McKinsey's 2024 life sciences survey found that while nearly every life science firm has experimented with generative AI, only about one third have scaled any use case beyond pilot. Only 5 percent of respondents reported AI as a competitive differentiator yielding consistent financial gains.
The 5 percent figure matters. It means 95 percent of pharma AI experimentation is producing pilots, learnings, and slide decks rather than financial outcomes.
The Actual Math
The 7.2 million dollar number is not the whole cost. It is the average sunk cost from accounting visibility. The total organizational cost of a failed pharma AI pilot includes layers most board reporting does not capture.
Vendor and platform spend. The visible line item. Ranges from 25,000 dollars to 100,000 dollars per use case at pilot scale, scaling into seven and eight figures for enterprise deployments.
Hidden infrastructure costs. Manufacturing enterprises encounter hidden expenses that inflate total AI ownership costs by 200 to 400 percent above initial vendor quotes. 65 percent of IT leaders report unexpected consumption based AI charges, with actual costs frequently exceeding estimates by 30 to 50 percent.
Data preparation. 96 percent of organizations begin AI projects without sufficient high quality training data. Acquiring or labeling datasets adds an unplanned 10,000 to 90,000 dollars per use case before the model even runs.
Internal time. A typical pharma AI pilot consumes meaningful capacity across IT, data science, commercial, medical affairs, compliance, and procurement. The fully loaded internal time on a failed pilot is rarely tracked but routinely exceeds the visible vendor spend.
Production scale cost overrun. MIT's 2025 research found that GenAI cost overruns average 380 percent at production scale versus pilot projections. The pilot budget is almost never the production budget.
Opportunity cost. The most expensive line is the one that does not appear in any spreadsheet. While a failed pilot occupies a team for 9 to 18 months, the use case the team did not pursue continues to compound for a competitor that built first.
Reputational cost. Pharma vendor relationships are small and incestuous. A high profile failed pilot with one vendor reshapes the company's willingness to engage the next one. Internal stakeholders who advocated for the project lose political capital. The next AI proposal arrives in a colder room.
Stack those together and the 7.2 million dollar sunk cost looks like a floor, not an estimate.
Why Pharma AI Pilots Actually Fail
The intuitive answer is technology. The data says otherwise.
A 2025 analysis of 140 enterprise AI implementations found that only 23 percent of failures were caused by model performance, data quality, or integration complexity. The remaining 77 percent came down to strategy, governance, and change management.
The pharma specific pattern repeats four root causes.
Data foundation. AI models are only as strong as the data they consume. Pharma data is fragmented across commercial, medical, regulatory, and manufacturing systems with inconsistent governance and quality. Most pilots discover the data gap mid build, not before scoping.
Infrastructure and integration. Infrastructure limitations account for 64 percent of GenAI scaling failures. Pilots are typically built on isolated sandboxes that do not survive the move into validated, integrated production environments.
Regulatory and validation gap. Many pharma AI initiatives are built like consumer tech products rather than regulated systems. Black box algorithms, undocumented model changes, and the absence of validation plans create regulatory risk that surfaces at exactly the wrong moment, usually right before launch.
Strategy and governance. The dominant failure mode. Pilots get launched without a clear business owner, without measurable success criteria, without alignment between IT, business, and compliance, and without a credible path from pilot to production. The pilot ends in a slide deck because that is what it was always going to produce.
What Changes When You Cost The Pilot Correctly
When pharma boards see the real number, three things shift.
The first is scoping discipline. Pilots stop being framed as exploration and start being framed as conditional production deployments. The success criteria for moving from pilot to production are defined before the pilot starts, not after.
The second is governance investment. The 77 percent of failures that come from strategy and governance can be addressed with structural investment in the layer pharma typically underfunds: AI operating model, accountability ownership, data governance, and validation frameworks. This investment is small relative to the cost of a single failed pilot.
The third is vendor management. Boards begin demanding scaling commitments, not just pilot deliverables, from vendor contracts. The vendor's incentive aligns with production deployment rather than pilot completion.
The Implication
A 7.2 million dollar failure is not a learning. It is a board level capital allocation event that just did not show up on the dashboard as one.
Pharma's AI investment cycle is accelerating. The companies that internalize the real cost of a failed pilot will redirect capital toward the small number of high probability production deployments. The companies that keep budgeting from the vendor quote will accumulate failed pilots until the board notices.
By that point, the cost will not be 7.2 million dollars. It will be the position your competitor has built while you were running pilots.
